Dexamethasone for Post Traumatic Headache
Primary Purpose
Post-Traumatic Headache
Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Dexamethasone
Metoclopramide 10mg
Sponsored by
About this trial
This is an interventional treatment trial for Post-Traumatic Headache
Eligibility Criteria
Inclusion Criteria:
- Included patients will be adults who meet International Classification of Headache Disorders criteria for acute post-traumatic headache. These are as follows:
- Traumatic injury to the head has occurred
- Headache has developed within 7 days of injury to the head
- Headache is not better accounted for by another diagnosis (eg, migraine or tension-type headache)
- The headache must be rated as moderate or severe in intensity at the time of initial evaluation.
Exclusion Criteria:
- Patients will be excluded if more than ten days have elapsed since the head trauma, if the headache has already been treated with an anti-dopaminergic medication, or for medication allergies or contra-indications including pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.
Sites / Locations
- MontefioreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Dexamethasone
Placebo
Arm Description
Dexamethasone 10mg IV + metoclopramide 10mg IV
Placebo IV + metoclopramide 10mg IV
Outcomes
Primary Outcome Measures
Moderate or Severe headache after Emergency Department discharge
Rating headache moderate or severe on a scale of severe, moderate, mild, or none
Secondary Outcome Measures
Sustained headache relief
Achieving a headache intensity of mild or none in the emergency department without use of rescue medication and maintaining that level for 48 hours without use of rescue medication.
Post concussive symptom scale
The Sport Concussion Assessment Tool (SCAT) Post Concussion Symptom Scale (PCSS). On this validated instrument, patients rate 22 concussive symptoms on a 0 to 6 scale, with 6 signifying more severe pain
Full Information
NCT ID
NCT04799015
First Posted
March 11, 2021
Last Updated
February 21, 2023
Sponsor
Montefiore Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT04799015
Brief Title
Dexamethasone for Post Traumatic Headache
Official Title
A Randomized Study of Dexamethasone as Adjuvant Therapy for Acute Post-traumatic Headache
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 24, 2021 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Montefiore Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized study of intravenous metoclopramide + intravenous dexamethasone versus intravenous metoclopramide for patients with acute post-traumatic headache.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-Traumatic Headache
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
162 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Dexamethasone 10mg IV + metoclopramide 10mg IV
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo IV + metoclopramide 10mg IV
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
Dexamethasone 10mg IV
Intervention Type
Drug
Intervention Name(s)
Metoclopramide 10mg
Intervention Description
Metoclopramide 10mg IV
Primary Outcome Measure Information:
Title
Moderate or Severe headache after Emergency Department discharge
Description
Rating headache moderate or severe on a scale of severe, moderate, mild, or none
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Sustained headache relief
Description
Achieving a headache intensity of mild or none in the emergency department without use of rescue medication and maintaining that level for 48 hours without use of rescue medication.
Time Frame
48 hours
Title
Post concussive symptom scale
Description
The Sport Concussion Assessment Tool (SCAT) Post Concussion Symptom Scale (PCSS). On this validated instrument, patients rate 22 concussive symptoms on a 0 to 6 scale, with 6 signifying more severe pain
Time Frame
48 hours and 7 days after emergency department discharge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Included patients will be adults who meet International Classification of Headache Disorders criteria for acute post-traumatic headache. These are as follows:
Traumatic injury to the head has occurred
Headache has developed within 7 days of injury to the head
Headache is not better accounted for by another diagnosis (eg, migraine or tension-type headache)
The headache must be rated as moderate or severe in intensity at the time of initial evaluation.
Exclusion Criteria:
Patients will be excluded if more than ten days have elapsed since the head trauma, if the headache has already been treated with an anti-dopaminergic medication, or for medication allergies or contra-indications including pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin Friedman, MD
Phone
718-920-6626
Email
befriedm@montefiore.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin Friedman, MD
Organizational Affiliation
Montefiore Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Montefiore
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Friedman, MD
Phone
718-920-6626
Email
befriedm@montefiore.org
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Dexamethasone for Post Traumatic Headache
We'll reach out to this number within 24 hrs